# NanoBioAnalytical (NBA) Platform to Decipher Extracellular Vesicles Secreted by Microvascular Endothelial Cells Under Benzo[a]pyrene Exposure

**Authors:** Geetika Raizada, Joan Guillouzouic, Alain Rouleau, Eric Lesniewska, Eric Le Ferrec, Céline Elie-Caille, Wilfrid Boireau

PMC · DOI: 10.3390/bios15020103 · Biosensors · 2025-02-11

## TL;DR

This study uses a new biosensor platform to analyze how exposure to benzo[a]pyrene affects extracellular vesicles from endothelial cells.

## Contribution

The novel NBA platform combines SPRi and AFM to profile EVs under cytotoxic stress, revealing changes in size and marker expression.

## Key findings

- B[a]P exposure alters EV capture on ligands like Anti-CD36 and Anti-CD81.
- EVs from treated cells are larger and show potential cytotoxicity biomarkers.
- SPRi and AFM together reveal EV heterogeneity linked to toxicological stress.

## Abstract

Recent advances in the clinical extracellular vesicles (EVs) field highlight their potential as biomarkers for diverse diseases and therapeutic applications. This study provides an in-depth characterization of 10k EVs from human microvascular endothelial cells (HMEC-1) exposed to benzo[a]pyrene (B[a]P), a polycyclic aromatic hydrocarbon found in food and smoke. Given EVs’ complexity, with numerous surface and cargo proteins, phenotyping remains challenging. Here, we introduce a multiplex biosensor, in µarray format, for profiling EVs from distinct cellular conditions, employing a multimodal approach that combines surface plasmon resonance imaging (SPRi) and in situ atomic force microscopy (AFM) to decipher EVs’ biochemical and biophysical properties. SPRi experiments showed notable EV capture differences on ligands such as Anti-CD36, Anti-CD81, and Anti-ApoA between treated and control conditions, likely due to B[a]P exposure. A complementary AFM study and statistical analyses revealed size differences between EVs from treated and control samples, with ligands like Annexin-V, Anti-CD36, and Anti-VEGFR1 emerging as ligands specific to potential cytotoxicity biomarkers. Our findings suggest that B[a]P exposure may increase EV size and alter marker expression, indicating phenotypic shifts in EVs under cytotoxic stress. The original combination of SPRi and AFM reveals valuable data on the phenotypical and morphological heterogeneities of EV subsets linked to cytotoxic stresses and highlights the potential of EVs as specific toxicological markers.

## Linked entities

- **Proteins:** CD36 (CD36 molecule (CD36 blood group)), CD81 (CD81 molecule), APOA1 (apolipoprotein A1), FLT1 (fms related receptor tyrosine kinase 1)
- **Chemicals:** benzo[a]pyrene (PubChem CID 2336), B[a]P (PubChem CID 2336)

## Full-text entities

- **Genes:** CD36 (CD36 molecule (CD36 blood group)) [NCBI Gene 948] {aka BDPLT10, CHDS7, FAT, GP3B, GP4, GPIV}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, APOA1 (apolipoprotein A1) [NCBI Gene 335] {aka AMYLD3, HPALP2, apo(a)}, CD81 (CD81 molecule) [NCBI Gene 975] {aka CVID6, S5.7, TAPA1, TSPAN28}, FLT1 (fms related receptor tyrosine kinase 1) [NCBI Gene 2321] {aka FLT, FLT-1, VEGFR-1, VEGFR1}
- **Diseases:** cytotoxicity (MESH:D064420)
- **Chemicals:** B[a]P (MESH:D001564), polycyclic aromatic hydrocarbon (MESH:D011084)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HMEC-1 — Homo sapiens (Human), Transformed cell line (CVCL_0307)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11852858/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11852858/full.md

## References

26 references — full list in the complete paper: https://tomesphere.com/paper/PMC11852858/full.md

---
Source: https://tomesphere.com/paper/PMC11852858